Kimberly Westrich, MA, Director of Value & Access Strategy at Xcenda/AmerisourceBergen kicks off AMCP's 2023 annual meeting in San Antonio with her discussion on value framework assessments. Westrich mentioned one of the obstacles payers come across when using value assessment frameworks in decision-making is either not having enough information or having the right kind of information.
Kimberly Westrich, MA, Director of Value & Access Strategy at Xcenda/AmerisourceBergen kicks off AMCP's 2023 annual meeting in San Antonio with her discussion on value framework assessments. Westrich mentioned one of the obstacles payers come across when using value assessment frameworks in decision-making is either not having enough information or having the right kind of information.
When asked if is there a way to simplify these frameworks when it comes to administrative complexity, Westrich said it can be really complicated.
"I think it's natural to want to simplify it. The irony of simplification in this particular situation is that it can actually not serve patient's best interests," she said. "So, patients are different. If you have two patients, and they're both taking the same treatment, they may respond to that treatment differently. So if you're thinking about the value of that treatment to each of those patients, it's going to be a different value to each patient. Now, a simplified value assessment is often, unfortunately, sort of a one size fits all based on a population average, that doesn't actually serve the needs of those individual patients."
Specialty Drugs Dominate Pharmaceutical Frontier in 2025
April 15th 2025In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.
Read More
340B Program Is Driving Up Costs and Needs Urgent Reform | AMCP Annual 2025
April 7th 2025At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a conversation with Managed Healthcare Executive.
Read More
Exploring the Wide World of GLP-1s | AMCP Annual 2025
April 3rd 2025Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.
Read More